
Meteorite that tore through southeastern US skies this summer determined to be older than Earth itself, researchers say
Fragments of the extraterrestrial rock were turned over to scientists after they fell to Earth this summer to determine their classification and origin.
The University of Georgia received 23 of the 50 grams of the McDonough Meteorite, named after the Georgia city where it ripped through the roof and ceiling of a home, according to the university.
'This particular meteor that entered the atmosphere has a long history before it made it to the ground of McDonough,' Scott Harris, a researcher in the UGA Franklin College of Arts and Sciences' department of geology, said in the news release.
Harris determined the meteorite to be a Low Metal (L) ordinary Chondrite – a type of stony meteorite – and thus 20 million years older than Earth by 'using optical and electron microscopy,' the university said.
'It belongs to a group of asteroids in the main asteroid belt between Mars and Jupiter that we now think we can tie to a breakup of a much larger asteroid about 470 million years ago,' Harris said in the release. 'But in that breakup, some pieces get into Earth-crossing orbits, and if given long enough, their orbit around the sun and Earth's orbit around the sun end up being at the same place, at the same moment in time.'
UGA is also working with partners at Arizona State University to submit the meteorite's name and findings to the Nomenclature Committee of the Meteoritical Society, Harris said. Harris also plans to publish a scientific paper about the rock to further understand the potential threats meteorites pose.
'One day there will be an opportunity, and we never know when it's going to be, for something large to hit and create a catastrophic situation. If we can guard against that, we want to,' he said.
The American Meteor Society received numerous reports of a fireball over the region on June 26, CNN previously reported. The reports came during the Bootids meteor shower, a lower-level celestial event that was ongoing during the last week of June.
A Henry County, Georgia, resident had reported at the time that a rock – which would later be identified as the McDonough Meteorite – fell through their ceiling around the same time the June fireball occurred, according to the National Weather Service in Peachtree City. The object had broken through the roof and ceiling before cracking the flooring inside the home.
'I suspect that he heard three simultaneous things. One was the collision with his roof, one was a tiny cone of a sonic boom and a third was it impacting the floor all in the same moment,' Harris said in the news release. 'There was enough energy when it hit the floor that it pulverized part of the material down to literal dust fragments.'
The resident told Harris he's still finding specks of space dust around his living room from the collision, according to the university. The rock is the 27th meteorite in history recovered in Georgia and the sixth witnessed fall.
Seeing a daytime fireball is a rare occurrence: Fireballs are easier to view at night, but must be much brighter to be visible during the day, the American Meteor Society says. It's also 'quite rare' for sonic booms to be heard on the ground when a fireball occurs, according to the organization.
A fireball is an unusually bright meteor that reaches a magnitude over -4, which is brighter than Venus, according to the American Meteor Society. June's fireball reached a magnitude of around -14, the society told CNN, which would have made it brighter than the full moon.
It didn't take the McDonough space rock pummeling through roofs for others to spot it.
In Lexington County, South Carolina, dashcam video showed a big flash of light falling through the sky on June 26.
Brenda Eckard, 64, from Gilbert, South Carolina, previously told CNN she was driving home that June day when she saw a 'big flash in the sky come down and disappear.'
She first thought it was a meteor that 'almost looked like a firework,' Eckard said. Eckard then called her husband to check if their house was still standing.
The McDonough Meteorite is being stored at UGA for continued tests, according to UGA Today. Other pieces of it that fell on June 26 will be publicly displayed at the Tellus Science Museum in Cartersville, Georgia.
CNN's Devon Sayers, Brandon Miller and Zenebou Sylla contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology. As previously announced, AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. KLOTHO is a biotechnology company focused on the development of groundbreaking, disease-modifying cell and gene therapies using a human gene and protein derived from its patented form of the "anti-aging" Klotho gene. Dr. Joseph Sinkule, KLOTHO CEO, stated, "The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes. The initiation of manufacturing is a key milestone in the development of any biotech product, and the manufacturing of gene therapy products presents particular complications. KLOTHO is using AAVnerGene's cutting-edge 'AAVone' platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing our Klotho gene, so that the AAV particles containing our gene are at a higher-than-normal titer concentration, have fewer impurities, and can be optimized and produced faster than the old standard method. We believe that working with AAVnerGene as our development partner has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current 'triple transfection' manufacturing method." One of the major challenges facing AAV-vectored gene therapies is the propensity of the AAVs to home in on the liver and induce an inflammatory response that causes life-threatening side effects and even death. AAVnerGene created a series of specific tissue-targeting AAVs developed with its 'ATHENA' platform technology. Using the ATHENA system and tissue-specific targeting of the KLTO gene therapy product candidates containing KLTO's tissue-specific promoters will be proven to be highly beneficial and likely safer than the AAV vectors that traffic to the liver. AAVnerGene and Complexity of AAV-vectored Cell Lines Over the past 20 years of gene therapy, investigators and companies used a process called "triple transfection" whereby three DNA plasmids are transfected, or inserted, into the cell line called HEK293. The three plasmids contain sequences of the 'gene-of-interest', Rep/Cap sequences from AAV and 'Helper' sequences from Adenovirus to provide essential viral genes to enable replication and packaging of the AAV. As the HEK293 cells replicate and produce the viral proteins, the HEK293 cells assemble the proteins required to make the AAV particles containing the gene-of-interest inside the AAV particle. This is a complicated, tedious, labor-intensive process requiring optimization that may take several months or a year to complete. AAVnerGene developed a one-plasmid AAV packaging system called "AAVone," which dramatically increased the production efficiency, simplified the process, reduced the impurity, shortened the time and lowered the development cost. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOir@ About AAVnerGene, Inc. AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company's proprietary platforms include AAVone, a high-yield, single-plasmid AAV production system that dramatically reduces manufacturing costs, and ATHENA, an advanced capsid engineering platform enabling precise tissue targeting. AAVnerGene is dedicated to delivering affordable, scalable, and precision-engineered gene therapy solutions that accelerate clinical development across diverse therapeutic areas. Investor Contact and Corporate Communications – Daozhan Yu, CEO Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
6 minutes ago
- Forbes
Apex Wants To Bring Henry Ford-Style Mass Production To Satellites
At Apex Technology's new, brightly lit factory in Los Angeles, a monitor shows the vital signs and location of its first satellite as it orbits the Earth every 90 minutes. The stresses it's undergoing as it passes from blazing sunlight to the cold of night illustrate why making satellites is so hard – and expensive, said Apex's CEO and cofounder, Ian Cinnamon. 'Imagine your phone has to stay on for five years, and every 45 minutes you're going to put it in the oven and then the freezer,' said the fast-talking 33-year-old, with a toothy grin. The satellite, named Aries after Cinnamon's dog, a brown and white Havanese, was launched last year less than 12 months after Apex started work on it, in what they claim is a record time for a small satellite designed to be mass produced. It's a first step toward their goal of bringing Henry Ford-style mass production to the satellite industry. Past the monitor, in a clean room on the other side of a clear vinyl curtain, hairnet-wearing technicians work on another Aries satellite, which sits on a wheeled dolly at one of six stations on Apex's assembly line. Cinnamon says it's the wave of the future in the satellite industry, where factories have historically built a single spacecraft at a time. With cofounder and CTO Max Benassi, a former lead engineer at SpaceX, he plans to produce a dozen satellites a month at the factory. Satellite manufacturing has long been a bespoke business, with each spacecraft customized for their mission, like taking pictures of the Earth or beaming down TV signals. Elevated costs and delays have come with the territory. With more and more small satellites being launched into low-Earth orbit, Apex is trying to convince constellation developers that it would be faster and more affordable to use a standardized spacecraft instead. Apex is offering three different types of "buses," meaning the main body of the satellite, including power and control systems — customers just have to add their own sensors and other payloads. Like, say, weapons to shoot down intercontinental ballistic missiles, as envisioned for President Trump's Golden Dome. Similar to automakers, Apex offers different trim levels of its satellites, with options like more power, a fancier communications system and a choice between electrical or chemical propulsion. Otherwise Apex isn't changing a thing. 'You either take it or you leave it,' Cinnamon said. He thinks that reducing the complexity will be a winning formula for buyers of small satellites, like defense contractors and telecom companies. Cinnamon and Benassi see a lot of runway: Before they started Apex in 2022, the duo canvassed such buyers and said they heard universal dissatisfaction over delays, cost creep and poor quality. 'We want to be the first satellite bus manufacturer that people do not hate. That's our differentiator,' Cinnamon told Forbes . Apex's basic premise makes sense, said Caleb Henry, director of research at the space consultancy Quilty Analytics: Satellite operators have long recognized that buying standardized spacecraft would be advantageous. But the urge to seek more expensive custom solutions is powerful. 'They become their own worst enemy,' Henry said. Apex's executive team reviews blueprints of their first factory. From left, mission services chief Nirav Mehta, sales lead Andrew Berg, CEO Ian Cinnamon, CTO Max Benassi and manufacturing head Alex Verrelli. Ethan Pines for Forbes Satellite manufacturers booked $20 billion in revenue worldwide last year, according to the Satellite Industry Association. Apex hopes to contend for a big share of a growing pie as the U.S. military expands in space. Golden Dome alone could cost more than $800 billion, according to the Congressional Budget Office. Apex has a long way to go: the company only produced three satellites in 2024. It's aiming for 10 this year. Still, strong sales boosted its revenue last year to $60 million, Forbes estimates, mostly from predelivery payments for its Aries bus, which can carry up to 330 pounds of payload, and Nova, named after Benassi's bernadoodle, which can hold twice as much. (A third bus is in the works that can carry 1,000 pounds, called Comet, after a dog that an early employee flirted with adopting.) Cinnamon says that orders have topped $100 million from roughly a dozen customers, with defense accounting for about two-thirds. Apex is close-mouthed about who they are and what it's doing for them, citing government restrictions, but they include the British aerospace conglomerate BAE and defense tech startup Anduril, which has ordered at least one satellite as it seeks to expand into space. One commercial customer is Aetherflux, which plans to build a network of satellites in space to harvest solar power. Apex is set to deliver the bus for their first demo satellite Friday. Aetherflux's founder, the billionaire Robinhood cofounder Baiju Bhatt, was impressed enough by Apex to become an investor as well, praising Benassi's technical chops and Cinnamon's drive in an interview with Forbes . 'Those guys are hardworking, they're scrappy,' he said. Cinnamon says demand is so strong that they're exploring ways to accelerate their production ramp, which currently is slated to reach a rate of 144 satellites a year in 2028. The company raised $200 million in April to build out the ability to produce more of its own parts, increasing its total funding to $322 million in equity and debt. Backers include 8VC, Andreessen Horowitz, Point72 Ventures and XYZ Capital. The company's rapid progress has gained it a spot on this year's Next Billion-Dollar Startups list of 25 venture-backed companies Forbes thinks are most likely to reach a $1 billion valuation. Commercial activity in low-Earth orbit has exploded in recent years, but Apex may have muted prospects in the biggest market: telecommunications. The two companies building the largest constellations to provide broadband internet from space, SpaceX and Amazon, are making their own spacecraft in-house. Defense is its biggest opportunity. The Defense Department is keen to expand its satellite supplier base, and Apex's performance has been impressive so far, a Space Force officer told Forbes on the condition of anonymity since he wasn't authorized to speak publicly. 'The DOD is tired of spending a ton of money to either not get a capability delivered on time or to their expectations.' Apex has successfully worked through a series of the sort of small R&D contracts that the Pentagon uses to test out new companies, and in February it won a $46 million contract from the Space Force for an unspecified number of Aries satellites. (York Space Systems has filed a lawsuit alleging it was awarded without a proper competition.) Sitting at a desk in his office in front of a painting of his dog Aries in a space suit, Cinnamon said he's already convinced a couple of companies that have produced their own buses to try out Apex – and he's gunning for more. 'My dream would be every single major prime that's competing in Golden Dome [uses] the Apex satellite bus platforms.' The company's aim to dominate the satellite industry is underlined in its conference rooms, all named after apex predators: caiman, orca, hawk. The sign outside Cinnamon's office bears the name of the deadliest predator of all — human. Dangerous Mind Cinnamon grew up in Los Angeles, a son of sitcom writers. He showed a precocious ability for programming – and commerce. He sold video games online in elementary school and wrote a textbook for teens called Programming Video Games for the Evil Genius at age 15. (He later wrote another book in the Evil Genius series, on building drones.) Cinnamon fell in love with space, too, starting rocketry clubs at his middle and high school. He went to MIT to study aerospace engineering, but shifted tracks after deciding the program was a conveyor belt to a straitjacketed job at a giant defense contractor or with the government. 'I'd be fired within a few hours,' he laughs. 'Bureaucracy and I are not going to get along.' Technicians work on Aries satellite buses on Apex's assembly line. Courtesy of Apex Technology After earning a degree in brain science, he went to work for billionaire Mark Pincus at a startup incubator. On the side, Cinnamon cofounded a nonprofit that tried to use machine learning to make an HIV vaccine, an effort that won him a place in the 2015 Forbes 30 Under 30. In 2016, Cinnamon started a company called Synapse that developed an AI system to automatically detect weapons in the images captured by scanners at airport security checkpoints. The company struggled to clinch many customers, but he sold it in 2020 to Palantir, where he worked with satellite companies to apply his technology to classifying what was in the images they were capturing on Earth — and came to believe there was room for a better spacecraft maker. In the previous decade, the market began to shift from large, billion-dollar satellites in geosynchronous orbits to constellations of dozens to hundreds of smaller ones closer to Earth. Some companies had decided to build their own small satellites, like Earth observation pioneers Planet and Spire, and of course SpaceX. A flock of new startups had come on the scene to build smallsats for others, including the military, like Terran Orbital and York Space Systems. Cinnamon's customers at Palantir, and others he spoke to, weren't satisfied with them, he said. 'There was no satellite manufacturer who was able to keep up with that demand.' Apex's competitors, like the European aerospace giant Airbus and Terran, which was acquired in 2024 by Lockheed Martin, say they offer standardized platforms that they can produce at volume; Cinnamon argues that in reality their satellite models are just a starting point for customization. Fixing the product allows for faster manufacturing and more rapid delivery – as well as firm pricing, which Apex, in an industry first, is making public on its website, with a menu to run through the various options. The base version of Aries starts at $3.5 million and can be delivered in six months, the company says; fully loaded, the LEO version is $9.5 million and takes 12 months. Nova starts at $6 million. That's likely more than the cost to SpaceX of its narrowly tailored Starlink satellites, which the consultancy Quilty estimates have run up to a million apiece. But it's less than the prices the U.S. military's Space Development Agency has paid for the constellation it's building, ranging from an average of $15 million for communications satellites to $40 million to $45 million for missile tracking spacecraft. Apex has also designed its satellites to be easier to put together, allowing the startup to widen its hiring to lower-paid mechanics with auto experience. It aims to increase the share of components custom built in-house or by contractors to 90% from 50% now, on the conviction that suppliers won't be able to support its production expansion. Apex investor and board member Ross Fubini, founder of the venture capital firm XYZ, who previously backed Cinnamon at Synapse, said he's been impressed by the young entrepreneur's deft triangulation of a complicated market. 'A lot of the tension in this part of the business is you have to not do everything your customer wants,' he said. In the case of Golden Dome, the customer has yet to even define what it wants. But a host of other companies hungry for the opportunity have acquired startups making small satellites to stay relevant as the market for larger ones stagnated, including Lockheed (Terran), Raytheon (Blue Canyon) and Boeing (Millennium Systems). SpaceX, which has built over 9,000 satellites for its Starlink network, also could be a compelling option for the government – though seemingly less so following founder Elon Musk's falling out with Trump. Apex could be at a disadvantage unless it strikes a strong partnership with a prime contractor, said Micah Walter-Range, an industry consultant and former director of research at the Space Foundation. And Apex's drive to bring its supply chain in house to boost production brings a host of additional risks. 'It's possible to do all the things that they say they're going to do, but it comes down to the execution.' More from Forbes Forbes Starlink's Numbers Could Bring SpaceX's Valuation Crashing Down By Jeremy Bogaisky Forbes This Billionaire Immigrant Is Racing Elon Musk To Connect Your Phone From Space By Alex Knapp Forbes Robinhood's Billionaire Cofounder Wants To Set Up Hundreds Of Solar Panels In Space By Alex Knapp

Associated Press
6 minutes ago
- Associated Press
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ('Amphastar'), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today announced that it has entered into an exclusive license agreement ('Agreement') with Nanjing Anji Biotechnology Co., Ltd. ('Anji') for the development, manufacturing, use, and commercialization of three proprietary peptides, ('Licensed Products'), in the United States and Canada ('Territory'). The first product is based on the discovery by Anji of an endogenous peptide that demonstrates a novel mechanism of action that potentially suppresses the growth and metastasis of multiple poorly treated cancers. The second product is a novel peptide-docetaxel conjugate that targets a specific receptor, designed to improve the selectivity and bioavailability of docetaxel. It is designed to reduce docetaxel-induced toxicity, which will improve the efficacy and safety of current taxane therapies. The third product is an anti-vascular endothelial growth factor receptor (VEGFR) peptide of novel design, developed as a topical eye drop for the treatment of wet age-related macular degeneration (wAMD). It is intended to be an alternative to the routine eye injections used for current treatment. 'We are delighted to announce a strategic licensing agreement with Anji, whose cutting edge research and development expertise in peptide and polypeptide therapeutics aligns perfectly with Amphastar's mission to develop novel, proprietary, and innovative products,' said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer 'This collaboration significantly expands our pipeline with three potentially best-in-class peptide assets, targeting high-growth markets across oncology and ophthalmology. We believe this partnership builds upon Amphastar's legacy in successfully developing and commercializing peptide products and underscores our shared commitment to bringing transformative therapies to patients.' Under the terms of the Agreement, Anji grants Amphastar an exclusive license to intellectual property controlled by Anji related to the Licensed Products in the Territory. Additionally, Anji will receive a non-exclusive license from Amphastar for certain intellectual property to develop, make, use, and commercialize Licensed Products outside the Territory. Amphastar made an earnest money payment of $0.75 million and an upfront payment of $5.25 million to Anji upon signing the Agreement. The Agreement also includes additional potential development milestone payments of up to $42 million and sales milestone payments of up to $225 million, contingent upon the achievement of certain milestones based on annual net sales. Furthermore, Amphastar will pay Anji 5% royalty payments on net sales, with a maximum accumulated amount of $60 million for each Licensed Product. Anji will also pay Amphastar low single-digit royalty payments on net sales of Licensed Products based on any patents licensed by Amphastar to Anji under the Agreement. Anji may receive up to $453 million in total payments over the lifetime of the Agreement. The term of the Agreement will expire, on a Licensed Product-by-Licensed Product and region-by-region basis, on the tenth anniversary of the first commercial sale of such Licensed Product in the applicable region in the Territory, with Amphastar having the right to extend the Agreement until the earlier of an additional ten years or until the expiration, lapse, or invalidation of the last remaining valid claim of the patents licensed by Anji to Amphastar that cover the Licensed Products in the Territory. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. In recent years, the development of proprietary medicines has been a major strategic direction for the Company. Amphastar manufactures all of its drug products in the United States, and manufactures active pharmaceutical ingredients in the United States, China and France. Amphastar has multiple peptide and protein products commercialized in the US market and under development. Many of the Company's injectable finished products are used in hospital or urgent care settings while the inhalation products are sold in retail pharmacies. More information and resources are available at Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar. About Nanjing Anji Biotechnology Co., Ltd. Nanjing Anji Biotechnology Co., Ltd. is a high-tech enterprise located in Nanjing, China, focusing on the research and development of innovative peptide drugs and peptide-drug conjugates. The company possesses key technologies: (i) high-throughput endogenous micropeptide discovery technology (ii) computer-aided peptide drug design technology, along with (iii) a comprehensive preclinical drug evaluation platform. Forward-Looking Statements All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding the Agreement with Anji including its effects on Amphastar's pipeline, ability to bring additional products to market, ability to meet customer demand and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expect,' 'intend,' 'plan,' 'project,' 'believe,' 'estimate,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ending June 30, 2025, filed with the SEC on August 7, 2025. You can locate these reports through our website at and on the SEC's website at The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 980-9484 SOURCE: Amphastar Pharmaceuticals, Inc. press release